LUBIPROSTONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LUBIPROSTONE (LUBIPROSTONE).
Lubiprostone is a bicyclic fatty acid derivative that activates type 2 chloride channels (ClC-2) in the apical membrane of intestinal epithelial cells, increasing chloride secretion and resulting in increased intestinal fluid secretion and motility.
| Metabolism | Lubiprostone is rapidly and extensively metabolized in the stomach and jejunum via carbonyl reductase, forming a metabolite (M3) that is active. Minimal hepatic metabolism. |
| Excretion | Primarily fecal (approximately 55-65%) via biliary secretion as active metabolite (M3); <1% unchanged drug in urine. Renal excretion is negligible. |
| Half-life | Terminal elimination half-life of active metabolite M3 is approximately 11-13 hours; parent drug half-life is very short (<1 hour). The metabolite half-life supports twice-daily dosing. |
| Protein binding | Approximately 94% bound to proteins, primarily albumin. |
| Volume of Distribution | Apparent volume of distribution (Vd/F) is approximately 1.5 L/kg for active metabolite M3, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is very low (<1%) due to extensive first-pass metabolism; the active metabolite M3 achieves clinically relevant systemic concentrations. |
| Onset of Action | Oral: 5-12 hours after a single dose for increased stool frequency; clinical effect (bowel movement) typically observed within 24 hours. |
| Duration of Action | Duration of effect lasts throughout the dosing interval (12 hours) with consistent dosing; sustained improvement in bowel habits with chronic use. |
24 mcg orally twice daily with food.
| Dosage form | CAPSULE |
| Renal impairment | No dosage adjustment required for any degree of renal impairment. |
| Liver impairment | Child-Pugh Class B or C: 24 mcg once daily. |
| Pediatric use | Not established for patients under 18 years of age. |
| Geriatric use | No specific dose adjustment; standard adult dosing recommended, monitoring for diarrhea and electrolyte disturbances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LUBIPROSTONE (LUBIPROSTONE).
| Breastfeeding | Unknown if excreted in human milk. In lactating rats, lubiprostone and its metabolites are present in milk at concentrations similar to plasma. No M/P ratio available for humans. Caution advised; consider discontinuing nursing or drug based on importance to mother. |
| Teratogenic Risk | Pregnancy Category C. In animal studies, lubiprostone caused fetal loss and reduced fetal weights at doses 2-4 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. First trimester: No human data; risk cannot be excluded. Second and third trimesters: No specific data; potential for uterine hyperstimulation and preterm labor due to increased prostaglandin activity. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known or suspected mechanical gastrointestinal obstruction","History of hypersensitivity to lubiprostone or any excipients"]
| Precautions | ["Nausea: May occur; take with food to reduce risk.","Diarrhea: Severe diarrhea may occur; monitor patients.","Dyspnea: Chest discomfort and dyspnea have been reported; usually mild to moderate.","Symptomatic hypotension: May occur, especially in patients taking antihypertensives.","Bowel obstruction: Do not use in patients with known or suspected mechanical gastrointestinal obstruction."] |
Loading safety data…
| Fetal Monitoring | Monitor for gastrointestinal adverse effects (nausea, diarrhea) that may lead to dehydration or electrolyte imbalance. In pregnant patients, watch for signs of preterm labor or uterine contractions. No routine fetal monitoring required unless clinical symptoms arise. |
| Fertility Effects | In animal studies, no adverse effects on male or female fertility at up to 32 times the human dose. Human data limited; no known significant impact on fertility. |